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Summary objectives To provide nationally relevant information on the antimalarial efﬁcacy of chloroquine
(CQ), sulphadoxine–pyrimethamine (SP) and amodiaquine (AQ) in Sierra Leone, with a view to
updating antimalarial policy in the country.
methods Between October 2002 and May 2003, standard WHO methodology for in vivo efﬁcacy
assessment was used in ﬁve sites to study the therapeutic response of 6–59 months old uncomplicated
Plasmodium falciparum malaria cases treated with CQ (n ¼ 247), SP (n ¼ 353) or AQ (n ¼ 434).
Follow-up was of 28 days, with polymerase chain reaction genotyping to distinguish late recrudescences
from re-infections.
results Overall 85.3% of patients reached an analysable endpoint. CQ failure proportions were very
high, ranging from 39.5% (95% CI: 25.0–55.6) in Kabala to 78.8% (65.3–88.9) in Kailahun. Early
failures under CQ were frequent. SP efﬁcacy was also disappointing, with failure from 23.2% (13.9–
34.9) in Kabala to 46.1% (35.4–57.0) in Kailahun. AQ resistance was more moderate, ranging from
5.4% (1.8–12.1) in Makeni to 29.8% (20.3–40.8) in Kailahun, with almost no early failures. AQ also
provided more rapid fever and parasite clearance.
conclusion In a consensus meeting organized by the Ministry of Health and Sanitation, and based on
these ﬁndings, artesunate (AS) + AQ and artemether–lumefantrine (Coartem ) were identiﬁed as the
only options to rapidly replace CQ. The choice fell on AS + AQ because of expected high efﬁcacy, lower
cost in a blister presentation, and the absence of safety data on artemether–lumefantrine in pregnancy.
Donor support is required to support this policy change. Throughout Africa, as SP resistance increases,
these two regimens are probably the only options available while newer combinations are developed.
Efﬁcacy studies should focus on testing AQ and AS + AQ.
keywords Plasmodium falciparum, malaria, Sierra Leone, efﬁcacy, chloroquine, sulphadoxine–
pyrimethamine, amodiaquine, artesunate, policy
Introduction
In Sierra Leone, malaria is considered to be the top public
health problem. Transmission (mostly of the lethal form,
Plasmodium falciparum) is hyper- to holoendemic, with
bothentomologicalinoculationrateandparasiteprevalence
among the highest recorded anywhere (Barnish et al.
1993a). Malaria accounts for 48% of total outpatient
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presumptive),anddatafromthecapitalFreetownshow42%
of inpatient paediatric deaths and 11% of maternal deaths
are malaria related (Ministry of Health and Sanitation and
Partners 2004). In southern Sierra Leone, 27% of commu-
nity deaths were caused by malaria (Barnish et al. 1993b).
Despite this enormous disease burden, data on antima-
larial efﬁcacy were scarce. Armed conﬂict (1989–2000)
severely damaged health infrastructures and hampered all
malaria control efforts. In the mean time, chloroquine
(CQ) and sulphadoxine–pyrimethamine (SP) remained
respectively the ﬁrst- and second-line regimens for
uncomplicated malaria. The ﬁrst post-war studies (2001)
showed 8.3% failure of CQ in a small series carried out in
the capital Freetown (Ministry of Health and Sanitation
and Partners 2004), while in Matru, a town in the south-
west (Figure 1), failure was 61.8% for CQ and 22.4% for
SP (Bachy 2002). In order to update efﬁcacy information
on a national scale, and guide therapeutic policy change,
we conducted simultaneous in vivo efﬁcacy studies of CQ,
SP and amodiaquine (AQ) at ﬁve different sites in Sierra
Leone (Freetown, Kabala, Kailahun, Makeni and Matru).
Data from a sixth site (Kenema) were rejected because of
insufﬁcient quality and are not reported here.
Materials and methods
Study sites and population
The studies were conducted in urban (Freetown), semi-
urban (Makeni, Kabala) and rural (Kailahun, Matru)
settings (Figure 1), selected because of their geographical
spread, and due to the presence of a hospital-based
outpatient department supported by Concern Worldwide
(Freetown) or Me ´decins Sans Frontie `res (all other sites). In
each site, malaria accounted for at least one-third of all
consultations, admissions and inpatient deaths. Febrile
children aged under 5 years were referred to the study from
the routine hospital consultation, or nearby clinics. In
Kailahun, Liberian refugees constituted a signiﬁcant
proportion of patients.
Design and procedures
The studies were approved by the Ethics Committee of the
SierraLeoneMinistryofHealthandSanitation,andadhered
to the latest WHO recommendations for antimalarial
efﬁcacy assessment in high transmission settings (WHO
2003a). Children 6–59 months old with uncomplicated
malaria (deﬁned as P. falciparum density 2000–200 000
asexual parasites per ll, no febrile co-infections as detected
mainly by clinicians’ presumptive diagnosis, no severe
malnutrition,andnosignsofseveremalariaincludingsevere
anaemia deﬁned as haemoglobin below 5 g/dl) were inclu-
ded(day0)iftheirguardiansconsentedinwriting.Siteswere
instructed to include at least 50 (WHO 2003a) and, if
possible,97(alpha5%,precision10%atworst)childrenper
treatmentarm.Thesesamplesizeswereincreasedby10%to
allow for defaulters and unclassiﬁable endpoints.
Upon inclusion, children received 3-day 25 mg/kg CQ
(Nivaquine , Rho ˆne Poulenc), 1.25 mg/kg + 25 mg/kg SP
stat (Fansidar , Roche) or 3-day 30 mg/kg AQ (Camoqu-
ine , Parke Davis), systematically allocated in a 1:1:1 ratio
(except for Matru where only AQ was tested, as CQ and SP
data were already available). All study doses were directly
observedondays0–2.Post-treatmentvisitsoccurredondays
3, 7, 14, 21, 28, or any other day in case of recurrent illness.
At each visit, children were assessed clinically, axillary
temperature was recorded, and thick and thin blood smears
(stained with 3% Giemsa for 35 min) were inspected. Blind
re-readings of each smear were performed on site, and a
randomsampleof60to100persiteindependentlyreviewed
at the Mbarara University of Science and Technology
(Mbarara, Uganda). Haemoglobin was measured on days 0,
14 and 28 using a Lovibond  system (Assistant Co.,
Sondheim Rhon, Germany). Capillary blood spots were
taken on 3 mm Whatmann ﬁlter paper on day 0 and the day
of failure endpoint (see below), if this occurred after day 9.
Endpoint classiﬁcation
Efﬁcacy endpoints (failure or cure) were assigned based on
the latest WHO classiﬁcation (Table 1). In case of failure,
Makeni
Freetown
Kabala
Matru
Kailahun
LIBERIA
GUINEA
GUINEA
Atlantic 
Ocean
Figure 1 Location of study sites.
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for Kailahun, where a combination of artesunate (AS) and
SP was used). Children who, between days 4 and 28, had
parasitaemia but no symptoms were monitored closely for
clinical deterioration. No endpoint was assigned to
children who were included outside of eligibility criteria,
or who, after inclusion, vomited a study dose more than
once, developed a serious febrile comorbidity, had a
serious treatment-related adverse event, were infected with
a non-falciparum species, received non-study antimalarials
or antibiotics with antimalarial activity, or missed sched-
uled study visits.
In high-transmission settings, re-infections occur fre-
quently and confound late clinical failure (LCF) and late
parasitological failure (LPF) endpoints. So as to identify
true failures (recrudescences) among these, polymerase
chain reaction (PCR) genotyping analysis was performed at
the Division of Infection and Immunity, University of
Glasgow (Freetown, Kabala, Makeni sites) and at the
Laboratoire de Parasitologie-Mycologie, Bichat Hospital,
Paris (Kailahun, Matru sites) on P. falciparum DNA
extracted from the day 0 and failure day ﬁlter spots.
Procedures in these laboratories were mutually reviewed,
and relied on well-described protocols (Ranford-Cart
wright et al. 1997; Snounou et al. 1999) comparing the
day 0 and failure day alleles of the merozoite surface
proteins 1 and 2 (msp-1 and msp-2) gene loci (Standard
Operating Procedures for the University of Glasgow
methodology are freely available for download at
http://www.gla.ac.uk/ibls/II/lrc/protocols.htm). LCF or
LPF were conﬁrmed as true recrudescences if msp-1 and
msp-2 PCR ampliﬁcation bands were similar on day 0 and
the failure day. Conversely, cases in whom these bands
were different were classiﬁed as re-infections. In case of
simultaneous re-infection and recrudescence, the failure
endpoint was retained.
Data analysis
Data were entered in duplicate on Microsoft Excel  and
analysed per-protocol on SPSS  (SPSS Inc., Chicago, IL,
USA). Patients without a clear efﬁcacy endpoint were
excluded from the analysis. In each arm, failures with
missing PCR results were extrapolated as re-infections or
recrudescences by applying the ratio observed among
available results. Therefore, the total number of failures
in each arm consisted of [early treatment failures
(ETF) + LCF before or on day 9 + LCF and LPF con-
ﬁrmed as recrudescences by PCR + LCF and LPF with
missing PCR result and extrapolated to be recrudes-
cences]. Failure proportions at day 14 (without PCR
adjustment) were also calculated. Baseline characteristics
and failure proportions were compared within and among
sites using chi-square (categorical variables) and anova
(continuous variables) tests.
Results
Study proﬁle
Between October 2002 and May 2003, 2579 children were
screened, of whom 1595 (61.8%) had a P. falciparum
mono-infection, and 1034 (40.1%) met all inclusion
criteria (Table 2). In Freetown, CQ allocation was
increased (3:1:1 ratio) during the last 2 weeks of the study,
so as to reach the minimum sample size (50) in that arm,
considered critical for policy decisions. In Kabala, Kaila-
hun and Makeni, CQ allocation was stopped early due to
very poor efﬁcacy. However, Kabala (CQ) failed to achieve
the minimum sample size due to a number (nine) of
parasitaemic, but not yet symptomatic, children receiving
rescue treatment against protocol. In all arms but two,
losses to follow-up were <10% (in Kailahun, a refugee
camp was suddenly relocated). Other reasons for not
assigning clear endpoints were: rescue treatment given to
parasitaemic but asymptomatic children (34, 17 of whom
in Kabala), febrile comorbidities (17), intake of non-study
antimalarials (nine), repeated dose vomiting (four), non-
falciparum infection (four), inclusion outside criteria
(three), and one 56-month-old male case of severe pruritus
on day 2 following AQ treatment in Makeni. In Freetown,
one 8-month-old male (AQ arm) died in hospital on day 11
Table 1 Efﬁcacy endpoint classiﬁcation*
Endpoint Criteria
Early treatment failure Parasite density on
day 2 > day 0
Parasite density on
day 3 ‡ 25% of day 0
Fever in the presence of
parasites on day 3
Severe malaria in the presence of
parasites on days 1–3
Late clinical failure
(days 4–28)
Fever in the presence of parasites
on days 4–28
Severe malaria in the presence of
parasites on days 4–28
Late parasitological
failure (day 28)
Parasites without fever on day 28
Adequate clinical and
parasitological
response (day 28)
Follow-up completed without
meeting any of the above criteria
* In a 14-day study, this same classiﬁcation is used but endpoints
at day 14 are considered.
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slides yielded an endpoint-affecting discordance in <5% of
cases for each study site.
Patient characteristics
Baseline age, axillary temperature, parasite density and
middle-upper arm circumference differed signiﬁcantly
(P < 0.001) among sites (Table 3). Within sites, all arms
were comparable except for Makeni, where CQ-treated
children had signiﬁcantly lower parasitaemia (P ¼ 0.007)
and were more anaemic (P < 0.001). Excluding Freetown
(no haemoglobin results available), 88.2% (746/846) of
children had any anaemia (haemoglobin <11 g/dl), and
33.5% (283/846) had moderate anaemia (haemoglobin
<8 g/dl).
Treatment efﬁcacy
The PCR-adjusted day 28 failure proportions (Table 4)
were available for all arms except for Freetown CQ and SP,
where >50% of failures had no blood spot collected.
Overall, CQ performed very poorly, with up to three-
quarters of patients failing treatment. ETF were very
frequent, ranging from 16.3% (7/43) in Kabala to 34.6%
(15/52) in Kailahun. SP failure was already near or above
25%, with ETF ranging from 6.3% (6/96) in Makeni to
18.0% (16/89) in Kailahun. AQ failure was relatively low
everywhere except for Kailahun, and ETF were uniformly
rare, with most failures occurring after day 14. AQ was
superior (P < 0.02) to CQ everywhere, and signiﬁcantly
(P < 0.03) better than SP in Kailahun and Makeni (Free-
town comparisons based on day 14 results).
On day 2, no signiﬁcant differences in fever clearance
were observed between CQ (range: 67.0% in Makeni to
82.9% in Freetown) and SP (range: 66.3% in Kailahun to
87.8% in Kabala), but in all AQ arms >95% of patients
Table 2 Number (percentages) of patients included and
analysable per study site and arm
Site/arm
Number
included
No efﬁcacy endpoint
Analysable
at day
Lost to
follow-up
Other
reasons 14 28
Freetown 187
CQ 71 4 (5.6) 8 (11.3) 61 59
SP 58 4 (6.9) 4 (6.9) 51 50
AQ 58 1 (1.7) 3 (5.2) 56 54
Kabala 227
CQ 59 2 (3.4) 14 (23.7) 50 43
SP 85 6 (7.1) 10 (11.8) 80 69
AQ 83 12 (14.5) 5 (6.0) 74 66
Kailahun 259
CQ 57 5 (8.8) 0 (0.0) 53 52
SP 101 10 (9.9) 2 (2.0) 94 89
AQ 101 14 (13.9) 3 (3.0) 92 84
Makeni 276
CQ 60 4 (6.7) 6 (10.0) 56 50
SP 109 7 (6.4) 6 (5.5) 96 96
AQ 107 8 (7.5) 6 (5.5) 94 93
Matru 85
AQ 85 3 (3.5) 5 (5.9) 78 77
Total 1034 80 (7.7) 72 (7.0) 935 882
Total CQ 247 15 (6.1) 28 (11.3) 220 204
Total SP 353 27 (7.6) 22 (6.2) 321 304
Total AQ 434 38 (8.8) 22 (5.1) 394 374
Table 3 Patient characteristics at inclusion
Characteristic
Freetown
(n ¼ 187)
Kabala
(n ¼ 227)
Kailahun
(n ¼ 259)
Makeni
(n ¼ 276)
Matru
(n ¼ 85)
Age (months) 36 18 15 19 24
Median (IQR) 20–51 12–24 9–27 10–31 14–37
Parasite density (/ll) 18 999 26 402 17 394 28 159 28 615
Geometric mean (IQR) 7920–45 455 11 005–64 973 6800–41 666 11 603–70 543 12 500–65 425
Temperature ( C) 38.3 38.4 38.2 39.2 39.0
Median (IQR) 37.8–39.2 38.0–39.2 37.7–39.0 38.6–39.7 38.3–39.4
Gender 0.8 1.1 0.8 0.9 1.5
Ratio M/F 84/103 117/110 113/146 133/143 51/34
Haemoglobin (g/dl) n (%)
Moderate anaemia (<8 g/dl) Not reported 64 (28.2) 95 (36.7) 94 (34.2) 30 (35.3)
Mild anaemia (8–10.9 g/dl) 128 (56.4) 134 (51.7) 154 (56.0) 47 (55.3)
No anaemia (‡11 g/dl) 35 (15.4) 30 (11.6) 27 (9.8) 8 (9.4)
MUAC (mm) 149 146 147 143 151
Mean (IQR) 140–158 136–154 138–156 134–152 144–158
IQR, Inter-quartile range; MUAC, middle-upper arm circumference.
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Freetown AQ vs. SP). Less than half of CQ-treated patients
were parasite-free on day 3 (range: 38.5% in Kabala to
47.3% in Makeni), and up to two-thirds of those receiving
SP (range: 46.8% in Kabala to 70.4% in Freetown). AQ
provided the most rapid parasite clearance (range: 56.8%
in Kabala to 90.1% in Makeni; P < 0.04 for all compar-
isons with AQ except Kabala AQ vs. SP).
Discussion
These studies provide nationally relevant, synchronous and
urgently needed data on antimalarial efﬁcacy in Sierra
Leone, a war-affected country with very low health
indicators and a dramatically high malaria burden. Their
main strength is the appropriately long patient follow-up
(28 days), supported by PCR genotyping. Fourteen-day
follow-up studies are easier to carry out, but seriously
underestimate resistance, and should be avoided
(Stepniewska et al. 2004).
Sampling in these studies was problematic, as none of
the arms reached the ideal sample size (97), and one failed
to reach the minimum (50). This was mainly due to
insufﬁcient human resources, notably doctors and skilled
microscopists. In addition, the proportion of patients not
reaching an endpoint was mostly higher than the 10%
budgeted (WHO now recommends to plan for 20%). Our
studies also relied on an imperfect method of treatment
allocation, leaving open the possibility of prescriber bias.
Block randomization with sealed envelopes would have
been preferable, and made inter-arm comparisons more
reliable. Losses to follow-up and protocol violations were,
on the whole, acceptably low. However, a signiﬁcant
number of parasitaemic children received rescue treatment
before day 28 although they could not yet be classiﬁed as
LCF or LPF. The WHO methodology’s requirement to
withhold treatment in such cases was perceived as difﬁcult
to comply with by study clinicians, notably in Kabala for
CQ-treated children. Excluding these ‘probable failures’
from the analysis underestimates resistance, and explains
why in Kabala CQ failure seemed lower than elsewhere.
Despite these drawbacks, clear trends emerge from these
studies. Antimalarial resistance has reached crisis propor-
tions in Sierra Leone. CQ, the ﬁrst-line regimen, fails to
cure most children who receive it, and, for many, does not
even provide temporary improvement. SP resistance is also
advanced, although the drug has not been used as ﬁrst-line.
SP-resistant strains are rapidly spreading throughout Africa
and are favoured by high transmission (Talisuna et al.
2002, 2004). AQ remains acceptably efﬁcacious in Sierra
Leone, and provides fast fever and parasite clearance. AQ
resistance seems more stable over time (The East African
Network for Monitoring Antimalarial Treatment
(EANMAT) 2003). Efﬁcacy of all three drugs was poorest
in Kailahun: possible reasons include imperfect tablet
dispensation, younger age and thus lower immunity of
included children, and introduction of highly resistant
strains from neighbouring Liberia, where studies have
Table 4 Endpoints and failure proportions at day 14 (no PCR adjustment) and day 28 (PCR adjusted)
Treatment/site
Day 28 endpoints (before PCR)
Day 14 failure proportion (no
PCR adjustment)
Day 28 failure proportion (PCR
adjusted)
ETF LCF LPF ACPR n % 95% CI n % 95% CI
CQ
Freetown 15 10 15 19 37/61 60.7 47.3–72.9 40/59* 67.8 54.4–79.4
Kabala 7 18 6 12 30/50 60.0 45.2–73.6 17/43 39.5 25.0–55.6
Kailahun 18 21 9 4 39/53 73.6 59.7–84.7 41/52 78.8 65.3–88.9
Makeni 10 23 10 7 44/56 78.6 65.6–84.4 35/50 70.0 55.4–82.1
SP
Freetown 4 4 6 36 9/51 17.6 8.4–30.9 14/50* 28.0 16.2–42.5
Kabala 9 5 6 49 14/80 17.5 9.9–27.6 16/69 23.2 13.9–34.9
Kailahun 16 23 7 43 29/94 30.9 21.7–41.2 41/89 46.1 35.4–57.0
Makeni 6 15 15 60 13/96 13.5 7.4–22.0 23/96 24.0 15.8–33.7
AQ
Freetown 1 6 2 45 4/56 7.1 2.0–17.3 4/54 7.4 2.1–17.9
Kabala 2 9 14 41 8/74 10.8 4.8–20.2 12/66 18.2 9.8–29.6
Kailahun 1 30 19 34 9/92 9.8 4.6–17.8 25/84 29.8 20.3–40.7
Makeni 0 18 10 65 4/94 4.3 1.2–10.5 5/93 5.4 1.8–12.1
Matru 0 9 14 54 0/78 0.0 0.0–4.6 10/77 13.0 6.4–22.6
* No PCR adjustment. ACPR, adequate clinical and parasitological response.
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moderate AQ (Checchi et al. 2002b) resistance. Site-
speciﬁc patterns of health service utilization (which we did
not inquire about) might also explain geographical differ-
ences in efﬁcacy. Where home remedies and drug sellers are
often the ﬁrst curative choices, public structures might see
proportionally more resistant infections (i.e. cases that
cannot be managed at home), thus skewing the proﬁle of
children referred to the study.
Antimalarial resistance of P. falciparum is constantly
evolving. Failure to rapidly detect a decline in drug efﬁcacy
(in Sierra Leone’s case, a consequence of wartime neglect)
leads to greater morbidity and mortality (Trape 2001;
Zucker et al. 2003), and greatly complicates malaria
control. Resistant cases are at higher risk of severe malaria
(Olumese et al. 2002) and anaemia (Bjorkman 2002), are
more infectious due to persistent parasitaemia and higher
gametocyte carriage (Bousema et al. 2003), and their
diagnosis and management are more difﬁcult and expen-
sive. Our results highlight the urgent need to move away
from CQ, and monotherapies in general, in Sierra Leone.
To address our ﬁndings, a consensus meeting was
called by the Ministry of Health and Sanitation in March
2004, with participation from central government, dis-
trict medical authorities, WHO, donors, and the NGO
community. There was wide consensus that CQ use
should be discontinued, and that combination therapy
should replace it so as to improve cure rates and protect
partner drugs against further spread of resistant strains
(Nosten & Brasseur 2002). The therapeutic lifespan of
any SP-based combination would probably be short,
necessitating extensive efﬁcacy monitoring and an addi-
tional policy change in the near future. In accordance
with current WHO recommendations (WHO 2003b), the
choice was thus narrowed down to AS + AQ and
artemether–lumefantrine (Coartem
TM), and the former
was selected. Both combinations are well tolerated
(Bakshi et al. 2000; Adjuik et al. 2004). Artemether–
lumefantrine is highly efﬁcacious (van Vugt et al. 1999;
Epicentre, unpublished data), but its safety in pregnancy
has not yet been established, and it currently costs more
than AS + AQ (2.4 USD vs. 1.5 USD per adult blister
pack). Given the moderate AQ failure proportions
observed in Sierra Leone, AS + AQ efﬁcacy is expected
to be high, as shown elsewhere (Adjuik et al. 2002),
although it may need regular monitoring given the
somewhat alarming results from Kailahun (Rwagacondo
et al. 2004). Progressive phasing in of the combination
should be completed in 2006. In addition, SP mono-
therapy was retained for intermittent preventive treat-
ment (IPT) in pregnancy given the absence of safety data
on other potential IPT regimens.
Conclusion
Today, Sierra Leone faces a daunting task of rolling back
malaria. The decision to replace CQ with an efﬁcacious
artemisinin-based combination is a crucial step in the right
direction. This policy merits a sustained commitment from
international donors to support country-wide deployment
of AS + AQ, and ensure the combination is ﬁnancially
affordable for all citizens. Elsewhere in Africa, the
assumptions today, even where data are missing, should be
that CQ no longer works, and that SP efﬁcacy is waning.
Efﬁcacy studies should instead focus on selecting efﬁca-
cious alternatives. However, the choice may be increasingly
limited to AS + AQ and artemether–lumefantrine, at least
while newer combinations such as dehydroartemisinin–
piperaquine and AS–chlorproguanil–dapsone complete
regulatory trials (Olliaro & Taylor 2003). For pregnancy,
there may not be a choice at all. As there are no reports yet
of in vivo resistance to artemether–lumefantrine, reprodu-
cing efﬁcacy tests of this combination may have limited
beneﬁt. By contrast, studies of AQ and AS + AQ seem
presently most useful to guide therapeutic policy change.
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